Evidence map›Paper›PMID 36993723›Full record

ArticleResearch square2023

The Impact of Race and Age on Response to Neoadjuvant Therapy and Long-Term Outcomes in Black and White Women with Early-Stage Breast Cancer.

Elizabeth Terman, Jori Sheade, Fangyuan Zhao, Frederick M Howard, Nora Jaskowiak, Jennifer Tseng, Nan Chen, Olwen Hahn, Gini Fleming, Dezheng Huo and 1 more

Abstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Elizabeth TermanPritzker School of Medicine, The University of Chicago.ORCID 0000-0002-7378-4171
Jori SheadeDepartment of Medicine, Section of Hematology and Oncology, The University of Chicago.
Fangyuan ZhaoDepartment of Public Health Sciences, The University of Chicago.
Frederick M HowardDepartment of Medicine, Section of Hematology and Oncology, The University of Chicago.
Nora JaskowiakDepartment of Surgery, The University of Chicago.
Jennifer TsengDepartment of Surgery, City of Hope Orange County.
Nan ChenDepartment of Medicine, Section of Hematology and Oncology, The University of Chicago.
Olwen HahnDepartment of Medicine, Section of Hematology and Oncology, The University of Chicago.
Gini FlemingDepartment of Medicine, Section of Hematology and Oncology, The University of Chicago.
Dezheng HuoDepartment of Public Health Sciences, The University of Chicago.
Rita NandaDepartment of Medicine, Section of Hematology and Oncology, The University of Chicago.ORCID 0000-0001-5248-0876

Funding

Scholars in Oncology Associated Research (SOAR)R25CA240134 · NCI · UNIVERSITY OF CHICAGO · PI OLUFUNMILAYO F. OLOPADE · 2019 to 2026
$1.3M
NCI NIH HHS R25 CA240134
6 · The paper itself

Abstract

purposeThere are a paucity of data and a pressing need to evaluate response to neoadjuvant chemotherapy (NACT) and determine long-term outcomes in young Black women with early-stage breast cancer (EBC).

methodsWe analyzed data from 2,196 Black and White women with EBC treated at the University of Chicago over the last 2 decades. Patients were divided into groups based on race and age at diagnosis: Black women 40 years, White women 40 years, Black women 55 years, and White women 55 years. Pathological complete response rate (pCR) was analyzed using logistic regression. Overall survival (OS) and disease-free survival (DFS) were analyzed using Cox proportional hazard and piecewise Cox models.

resultsYoung Black women had the highest risk of recurrence, which was 22% higher than young White women (p=0.434) and 76% higher than older Black women (p=0.008). These age/racial differences in recurrence rates were not statistically significant after adjusting for subtype, stage, and grade. In terms of OS, older Black women had the worst outcome. In the 397 women receiving NACT, 47.5% of young White women achieved pCR, compared to 26.8% of young Black women (p=0.012).

conclusionsBlack women with EBC had significantly worse outcomes compared to White women in our cohort study. There is an urgent need to understand the disparities in outcomes between Black and White breast cancer patients, particularly in young women where the disparity in outcome is the greatest.

Identifiers

PMID36993723
PMCPMC10055663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.